17

CPI-455

17 Publications Verification

Cat. No.: HY-100421

CAS No.: 1628208-23-0

Purity: 98.31%

Target:

Histone Demethylase

Research Areas:

Cancer

CPI-455 is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

17

CPI-455 hydrochloride

17 Publications Verification

Cat. No.: HY-100421A

CAS No.: 2095432-28-1

Target:

Histone Demethylase

Research Areas:

Cancer

CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

14

DXd

14 Cited Publications

Cat. No.: HY-13631D

CAS No.: 1599440-33-1

Purity: 99.30%

Synonyms: Exatecan derivative for ADC

Target:

Topoisomerase ADC Payloads

Research Areas:

Cancer

DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

12

Sacituzumab govitecan

12 Cited Publications

Cat. No.: HY-132254

CAS No.: 1491917-83-9

Purity: 99.13%

Synonyms: IMMU-132

Target:

Antibody-Drug Conjugates (ADCs) TROP2

Research Areas:

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

12

Sacituzumab govitecan (solution)

12 Cited Publications

Cat. No.: HY-132254A

CAS No.: 1491917-83-9

Purity: 96.61%

Synonyms: IMMU-132 (solution)

Target:

Antibody-Drug Conjugates (ADCs) TROP2

Research Areas:

Cancer

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

10

Sacituzumab

10 Cited Publications

Cat. No.: HY-P99045

CAS No.: 1796566-95-4

Synonyms: HRS7; hRS7

Target:

ADC Antibodies TROP2

Research Areas:

Cancer

Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

8

Trastuzumab emtansine (solution)

8 Cited Publications

Cat. No.: HY-P9921A

CAS No.: 1018448-65-1

Synonyms: Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)

Target:

Antibody-Drug Conjugates (ADCs) EGFR

Research Areas:

Cancer

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

8

Trastuzumab emtansine

8 Cited Publications

Cat. No.: HY-P9921

CAS No.: 1018448-65-1

Synonyms: Ado-Trastuzumab emtansine; PRO132365; T-DM 1

Target:

Antibody-Drug Conjugates (ADCs) EGFR

Research Areas:

Cancer

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

8

SKI II

8 Cited Publications

Cat. No.: HY-13822

CAS No.: 312636-16-1

Purity: 99.25%

Target:

SphK Dihydroceramide Desaturase 1 (DES1) Apoptosis Reactive Oxygen Species (ROS) mTOR PERK Keap1-Nrf2

Research Areas:

Infection Neurological Disease Cancer

SKI-II is an orally active dual-target inhibitor of SphK1/2 and DES1, with K_i values of 16 µM and 0.3 µM against SphK1 and DES1, respectively. SKI-II activates the PERK-Nrf2 antioxidant pathway by stabilizing Nrf2, and synergizes with Temozolomide (HY-17364) to induce oxidative/endoplasmic reticulum stress and cancer cell death under hypoxic conditions. In vivo, SKI-II inhibits SphK activity, promotes ceramide accumulation and apoptosis, and synergizes with Cisplatin (HY-17394) to reverse drug resistance via the ras/MAPK pathway. SKI-II reduces measles virus replication by inhibiting mTORC1 activity. SKI-II binds to VCP to induce M1 polarization, enhances host tolerance to Staphylococcus aureus infection, and exerts radioprotective effects through Nrf2 activation and accelerated DNA repair. SKI-II can be used in research related to glioblastoma, acute myeloid leukemia, gastric cancer, measles virus infection, Staphylococcus aureus infection, and acute radiation syndrome .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Apramycin

5 Cited Publications

Cat. No.: HY-17558

CAS No.: 37321-09-8

Synonyms: Nebramycin II

Target:

Bacterial Antibiotic

Research Areas:

Infection

Apramycin (Nebramycin II) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Apramycin sulfate

5 Cited Publications

Cat. No.: HY-B1329

CAS No.: 65710-07-8

Synonyms: Nebramycin II sulfate

Category:

Microorganisms Antibiotics Animal Husbandry Disease Research Antibacterial Disease Research Fields Other Antibiotics Cancer

Target:

Bacterial Antibiotic

Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Disitamab vedotin

5 Cited Publications

Cat. No.: HY-P9985

CAS No.: 2136633-23-1

Synonyms: RC48

Target:

Antibody-Drug Conjugates (ADCs) EGFR

Research Areas:

Cancer

Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC), formed by conjugation of the humanized anti-HER2 antibody Disitamab (HY-P99854) with drug-linker VcMMAE (HY-15575). VcMMAE consists of a cleavable MC-Val-Cit-PAB linker and the microtubule inhibitor MMAE (HY-15162). After binding to HER2 and undergoing endocytosis, Disitamab vedotin releases MMAE in lysosomes, which further inhibits microtubule assembly, arrests mitosis and induces apoptosis, while also exerting a bystander effect. Disitamab vedotin can be used in studies of HER2-positive breast cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

PKI 14-22 amide,myristoylated

4 Cited Publications

Cat. No.: HY-P1291

CAS No.: 201422-03-9

Target:

PKA Epigenetic Reader Domain Flavivirus

Research Areas:

Infection Neurological Disease

PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

PKI 14-22 amide,myristoylated TFA

4 Cited Publications

Cat. No.: HY-P1291A

Target:

PKA Epigenetic Reader Domain Flavivirus

Research Areas:

Infection Neurological Disease

PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive PKA inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

C6 Ceramide

4 Cited Publications

Cat. No.: HY-19542

CAS No.: 124753-97-5

Synonyms: C6-Cer; N-Hexanoylsphingosine

Target:

Apoptosis

Research Areas:

Cancer

C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

Compare

loading...